Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 2Leukemia, Hairy Cell 2Blast Crisis 2Sarcoma, Myeloid 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Myasthenia Gravis 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1

Interventions

Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Methotrexate 3Cytarabine 3venetoclax 2ponatinib 2merphos 2fludarabine phosphate 2Tacrolimus 2Idarubicin 2Etoposide 2Cyclosporine 2Cyclophosphamide 2Cladribine 2Busulfan 2midostaurin 1gilteritinib 1blinatumomab 1Thiotepa 1Sirolimus 1Razoxane 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Melphalan 1Injections 1Gemtuzumab 1Dexrazoxane 1Decitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Blast Crisis × Cladribine × 30 days × Clear all
NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT02115295 2026-05-20

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
508 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡